ABSTRACT
Objective:To investigate status quo of social support and social function in homeless schizophrenics.Methods:A total of 468 schizophrenics who received treatment in Hangzhou Seventh People's Hospital from January 2018 to December 2019 were included in this study. They were divided into homeless group ( n = 310) and non-homeless group ( n = 158) according to whether they had homeless behaviors. The basic information of admitted patients, level of social support and disease severity were surveyed among admitted patients using self-made questionnaire regarding basic information of admitted patients, Social Support Rating Scale, and Brief Psychiatric Rating Scale. Results:The numbers of schizophrenics in the aspects including male gender, rural household registration, non-local residents, no occupation, unmarried status, low level education, and age at 30-50 years in the homeless group were significantly higher than those in the non-homeless group ( χ2 = 3.58, 20.14, 18.69, 46.29, 33.16, 24.38, 29.75, all P < 0.05). The score for each SSRS domain and total score in the homeless group were significantly lower than those in the non-homeless group [(15.35 ± 5.42) points, (4.34 ± 2.78) points, (6.48 ± 1.89) points, (26.23 ± 7.35) points; (18.99 ± 3.78) points, (6.35 ± 3.23) points, (7.82 ± 2.01) points, (32.59 ± 7.02) points, t = 6.34, 10.52, 12.83, 14.68, all P < 0.001]. The score for each BPRS domain and total score in the homeless group were significantly higher than those in the non-homeless group [(19.35 ± 5.85) points, (22.58 ± 2.73) points, (18.74 ± 2.46) points, (18.48 ± 0.25) points, (16.38 ± 3.12) points, (79.43 ± 3.64) points; (12.92 ± 4.23) points, (16.24 ± 3.66) points, (16.97 ± 3.77) points, (10.58 ± 3.34) points, (6.36 ± 4.23) points, (62.72 ± 2.57) points, t = 9.92, 7.02, 6.33, 10.35, 15.74, 28.46, all P < 0.001]. Conclusion:The poor individual condition and low level of social support in patients with schizophrenia are important factors that cause homelessness.
ABSTRACT
Objective To investigate the effects of compound Haishe capsule combined with rivastigmine capsule on serum thyroid hormone ,inflammatory factors and coagulation function in patients with Alzheimer＇s disease (AD).Methods From January 2016 to January 2018,74 patients with AD in the Seventh People＇s Hospital of Hangzhou were randomly divided into control group and observation group according to the digital table ,with 37 cases in each group.The control group was treated with rivastigmine capsule ,while the observation group was treated with compound Haishe capsule on the basis of the control group.The two groups were treated for 6 months.The therapeutic effects of the two groups were compared.The changes of BEHAVE-AD and ADAS-Cog scores,thyroid hormones,inflammatory factors and coagulation function were compared before and after treatment.Results The total effective rate of the observation group was 94.59%(35／37),which was higher than 72.97%(27／37) of the control group(u＝6.366,P＜0.05).After treatment, the scores of BEHAVE -AD and ADAS -Cog in the observation group were (4.87 ± 0.64)points,(14.28 ±1.82 ) points, respectively, which were lower than those in the control group [( 8.91 ± 1.07)points,(18.93 ±1.25)points] ( t＝19.710,12.811,all P＜0.05).After treatment,the level of FT4 in the observation group was (13.09 ±0.71) pmol／L,which was higher than (12.30 ±0.52) pmol／L in the control group (t＝5.460,P＜0.05).After treatment,the levels of CRP and IL-6 in the observation group were (2.13 ±0.38)mg／L, (31.32 ±5.64)ng／L,respectively,which were lower than those in the control group [(3.47 ±0.61) mg／L,(58.93 ± 12.15)ng／L](t＝11.342,12.538,all P＜0.05).After treatment,the levels of D-dimer and Fib in the observation group were (519.82 ±10.29) μg／L,(3.21 ±0.32) ng／L,respectively,which were lower than those in the control group[(552.31 ±8.31) μg／L,(4.12 ±0.49) ng／L] ( t＝14.942,9.458,all P＜0.05).Conclusion Compound Haishe capsule combined with rivastigmine capsule is effective in the treatment of AD , and can improve thyroid hormone and coagulation function ,and reduce the level of inflammatory factors.
ABSTRACT
Objective@#To investigate the effects of compound Haishe capsule combined with rivastigmine capsule on serum thyroid hormone, inflammatory factors and coagulation function in patients with Alzheimer's disease(AD).@*Methods@#From January 2016 to January 2018, 74 patients with AD in the Seventh People's Hospital of Hangzhou were randomly divided into control group and observation group according to the digital table, with 37 cases in each group.The control group was treated with rivastigmine capsule, while the observation group was treated with compound Haishe capsule on the basis of the control group.The two groups were treated for 6 months.The therapeutic effects of the two groups were compared.The changes of BEHAVE-AD and ADAS-Cog scores, thyroid hormones, inflammatory factors and coagulation function were compared before and after treatment.@*Results@#The total effective rate of the observation group was 94.59%(35/37), which was higher than 72.97%(27/37) of the control group(u=6.366, P<0.05). After treatment, the scores of BEHAVE-AD and ADAS-Cog in the observation group were (4.87±0.64)points, (14.28±1.82)points, respectively, which were lower than those in the control group[(8.91±1.07)points, (18.93±1.25)points](t=19.710, 12.811, all P<0.05). After treatment, the level of FT4 in the observation group was (13.09±0.71)pmol/L, which was higher than (12.30±0.52)pmol/L in the control group (t=5.460, P<0.05). After treatment, the levels of CRP and IL-6 in the observation group were (2.13±0.38)mg/L, (31.32±5.64)ng/L, respectively, which were lower than those in the control group[(3.47±0.61)mg/L, (58.93±12.15)ng/L](t=11.342, 12.538, all P<0.05). After treatment, the levels of D-dimer and Fib in the observation group were (519.82±10.29)μg/L, (3.21±0.32)ng/L, respectively, which were lower than those in the control group[(552.31±8.31)μg/L, (4.12±0.49)ng/L](t=14.942, 9.458, all P<0.05).@*Conclusion@#Compound Haishe capsule combined with rivastigmine capsule is effective in the treatment of AD, and can improve thyroid hormone and coagulation function, and reduce the level of inflammatory factors.